Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
August 6, 2024
-
BUSINESS Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
-
REGULATORY Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
-
REGULATORY Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
-
BUSINESS Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
-
REGULATORY Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
-
BUSINESS Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
-
BUSINESS Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
-
BUSINESS EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
-
BUSINESS Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
-
BUSINESS Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
-
ORGANIZATION Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
-
BUSINESS Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
-
REGULATORY LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
-
BUSINESS Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
-
BUSINESS Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
-
REGULATORY Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
-
REGULATORY MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
-
REGULATORY Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
-
BUSINESS Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…